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2 
Abstract 24 
The combination of metformin hydrochloride (MTF) and glipizide (GLZ) is second-line 25 
medication for diabetes mellitus type 2 (DMT2). In the present study, elementary osmotic 26 
pump ( EOP) tablet is designed to deliver the combination of MTF and GLZ in a sustained 27 
and synchronized manner. By analyzing different variables of the formulation, sodium 28 
hydrogen carbonate is introduced as pH modifier to improve the release of GLZ, while ethyl 29 
cellulose acts as release retardant to reduce the burst release phase of MTF. A two-factor, 30 
three-level face-centered central composite design (FCCD) is applied to investigate the 31 
impact of different factors on drug release profile. Compared with conventional tablets, the 32 
EOP tablet demonstrates a controlled release behavior with relative bioavailability of 99.2% 33 
for MTF and 99.3% for GLZ. Data also shows EOP tablet is able to release MTF and GLZ in 34 
a synchronized and sustained manner both in vitro and in vivo.  35 
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3 
Introduction 46 
Diabetes mellitus type 2 (DMT2) is a metabolic disease characterized by insulin 47 
resistance and deficiency with high blood glucose level, which also referred as non-insulin 48 
dependent diabetes1. Increased thirst, frequent urination and constant hunger are usually 49 
accompanied with the onset of DMT2, followed by a series of complications if DMT2 is 50 
improperly treated2. Physical exercise and healthy diet are considered to be pivotal to treat 51 
DMT2 at first 3, 4, however medication is required to control blood glucose level if the disease 52 
deteriorates. According to international diabetes federation, more than 8% of the world 53 
population suffer from DMT2 and this number is expected to rise in the next two decades 5. 54 
Consequently, stable and effective medicine is in urgent needed for the treatment of DMT2. 55 
Anti-diabetic drugs aim at maintaining a normal blood glucose level by reducing plasma 56 
glucose concentration. Compared with injectable insulin formulation, oral anti-diabetic drugs 57 
are increasingly in favor of physicians due to their ease of use with better control of blood 58 
glucose level 6-8. Research has shown the mechanism of anti-diabetic drugs is either by 59 
improving the output and sensitivity of insulin itself, such as sulfonylurea, or regulating 60 
blood glucose absorption thereby maintaining a normal blood glucose level 9, 10. Biguanide 61 
and sulfonylurea is considered the second-line anti-diabetic drugs due to their relatively high 62 
bioavailability and marginal side effect. As one of biguanide derivatives, metformin 63 
hydrochloride (MTF) decreases blood glucose level by the inhibition of hepatic glucose 64 
production. Alternatively, as one of sulfonylurea derivatives, glipizide (GLZ) acts directly in 65 
pancreatic islet β-cells to facilitate the secretion of insulin 6, 11. The combination of MTF and 66 
GLZ is recommended by many physicians due to their complimentary effects in decreasing 67 
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blood glucose level in different mechanisms12, 13. This complimentary effect represents one of 68 
the advantages in the combination of MTF and GLZ. MetaglipTM (MTF and GLZ Tablets, 69 
Bristol-Myers Squibb, US) is very popular in the diabetics worldwide. However, the 70 
fluctuation of blood glucose concentration caused by traditional fast release preparation could 71 
induce serious side effects. Hence, the sustained release anti-diabetic agents attract so much 72 
attention of researchers. Because they could maintain a steady blood drug level and reduce 73 
dosage strength and dosing frequency14. Among these sustained drug delivery systems, 74 
osmotic pump system is much more superior to others because of its more stable blood drug 75 
level, better in vitro and in vivo correlation and free from the influence of physiological 76 
factors like pH and gastrointestinal peristalsis15. 77 
Recently, osmotic pump system has made a substantial progress in the delivery of 78 
different drugs with varied water solubility16. Apart from chemical drugs, many emulsions, 79 
nanoparticles, traditional Chinese medicines and compound medicines could also be 80 
delivered by this technology. Lanlan Wei et al. reported a novel self-emulsion carvedilol 81 
elementary osmotic pump17, Xi Zhang et al. have investigated the controlled release of a 82 
cyclosporine self-nanoemulsifying preparation through osmotic pump technology18, Dandan 83 
Liu et al. studied the delivery of carvedilol nanosuspension through an osmotic pump 84 
capsule19. The intention of this design is to take advantage of the merits of emulsion and 85 
nanoparticle—improving drug absorption and bioavailability, meanwhile controlling drug 86 
release and maintain blood drug level. The osmotic pump preparation of traditional Chinese 87 
medicines and compound medicines could make good use of the synergism of different drugs 88 
and reduce the fluctuation of blood drug concentration20, 21. 89 
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Hence, considering the connection of MTF and GLZ and sustained drug release, we 90 
investigated MTF and GLZ elementary osmotic pump (EOP). Generally, EOP is only suited 91 
to the drug having high water solubility like MTF, and not suitable for drugs with low 92 
solubility like GLZ15, 22. Because EOP could not offer sufficient driving force for insoluble 93 
drug to reach complete drug release. However, In terms of the EOP system of MTF and GLZ, 94 
MTF could act as an osmotic agent which generates powerful osmotic pressure to facilitate 95 
the release of GLZ, which has been proved to be true in many investigations23, 24. Therefore, 96 
the sustained and synchronized release profiles of MTF and GLZ are achieved by the 97 
employment of EOP system. 98 
In the present study, we establish an EOP formulation of MTF and GLZ with sustained 99 
and synchronized release profile to realize synergistic effect of the two drugs and maintain 100 
stable, prolonged drug level. Formulation variables are investigated by a number of factors, 101 
including tablet strength and membrane coating thickness 25. A 2-factor, 3-level face-centered 102 
central composite design (FCCD) is applied to optimize the formulation26, 27. Mathematical 103 
and graphical models are also implemented to study the impact of variables on release 104 
profiles. At last, the pharmacokinetics study of the optimized EOP tablet is performed in 105 
beagle dogs 106 
Materials and Methods 107 
Materials 108 
Metformin hydrochloride was purchased from Jiameng Pharmaceutical Co. Ltd. (Anhui, 109 
China). Glipizide was a gift sample from Sciecure Pharmaceutical Co. Ltd. (Beijing, China). 110 
Plasdone® K-90 (PVP K-90) was a gift sample from ISP Technologies Inc. (New Jersey, 111 
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USA). Ethyl cellulose (EC), sodium hydrogen carbonate and magnesium stearate were 112 
purchased from Bodi Chemical Co. Ltd. (Tianjin, China). Cellulose acetate (CA) was 113 
purchased from Sinopharm Chemical Reagent Co. Ltd. (Shanghai, China). Polyethylene 114 
glycol (PEG-400, 1500, 4000; the number is the molecular weight of PEG) was purchased 115 
from Kermel Chemical Reagent Co. Ltd. (Tianjin, China). Metformin hydrochloride and 116 
glipizide tablets were purchased from Lifeon Pharmaceutical Co. Ltd. (Anhui, China). All 117 
other ingredients were in analytical grade. 118 
Methods 119 
Preparation of core tablet 120 
MTF, GLZ, PVP K-90, EC and sodium hydrogen carbonate were passed through sieve 121 
No. 80 (opening size, 180 µm) separately. Drugs and all the other ingredients were weighed 122 
by balance and mixed in mortar. Granules were prepared by wet granulation using 95% 123 
alcohol as a moistening agent and passed through sieve No. 20 (opening size, 850 µm). The 124 
granules were dried at 40 °C for 2 h and passed through sieve No. 18 (opening size, 1000 125 
µm). Magnesium stearate was blended with dry granules and compressed into tablets using a 126 
single station punching machine (Shanghai No. 1 Pharmaceutical Device Co., Shanghai, 127 
China) fitted with 11 mm concave punches. 128 
Coating of core tablet 129 
The osmotic pump tablets were prepared with a semi-permeable membrane to obtain the 130 
desired release profile. Coating solution was prepared by dissolving CA and PEG in a 131 
solution of acetone and water (95:5, v/v). Core tablets were placed in the coating pan 132 
(Shanghai Tianfan Machinery Factory, Shanghai, China) along with 100 g placebo tablets. 133 
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Pan-rotating rate was 35 rpm, spray rate was 6 mL/min, and drying temperature was 30 °C. 134 
Coating process continued until desired weight was achieved on tablet core. The coated 135 
tablets were dried overnight at 40 °C to remove the residual solvent. 136 
In vitro dissolution study 137 
In vitro dissolution study was performed using USP II (paddle) apparatus (ZRS-6G, 138 
Tianjin Tianda Tianfa Technology Co. Ltd., Tianjin, China). A 0.05 M pH 6.8 phosphate 139 
buffer of 1000 ml was used as the dissolution medium maintained at 37 ± 0.5 °C) at a rotation 140 
speed of 50 rpm. 5 ml samples were withdrawn from the dissolution medium at 0, 2, 4, 6, 8, 141 
10, and 12 h and filtered through 0.45 μm cellulose nitrate filters in 30 seconds28. Each study 142 
was performed in triplicate and the mean values were recorded accordingly. 143 
Determination of MTF: 144 
   The filtrated sample was diluted with pH 6.8 phosphate buffer (dissolution medium) and 145 
determined at 233 nm by UV spectrophotometric29 (T6, Beijing Purkinje General Instrument 146 
Co.,Ltd., Beijing, China). 147 
Determination of GLZ:  148 
The filtrated sample was analyzed by HPLC30 (L6-P6, Beijing Purkinje General 149 
Instrument Co. Ltd., Beijing, China). The separation of GLZ in dissolution sample was 150 
performed on a Diamonsil C18 column (5 μm, 200 × 4.6 mm, Dikma). Mobile phase was 151 
consisted of 0.025 M pH 6.0 potassium dihydrogen phosphate buffer and methanol (40:60, 152 
v/v). The mobile phase was pumped at a flow rate of 1 ml/min. The wavelength of UV 153 
detector was set at 225 nm. The injection volume was 20 μl. 154 
Comparison of in vitro release profile 155 
8 
The method of similarity factor (f2) was recommended by the Food and Drug 156 
Administration (FDA) for dissolution profile comparison 31, 32. Two dissolution profiles were 157 
considered to be similar when the value of f2 was between 50 and 100. The f2 was calculated 158 
using the following equation: 159 
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where n was the number of time points, Rt was the dissolution value of the reference profile 161 
at time point t and Tt was the test profile at the same time point. The equation was applied to 162 
the evaluation of differences between the formulations. Rt and Tt were replaced with the 163 
dissolution value of the two formulations, respectively.  164 
Design of EOP tablets 165 
As described in Table 1, different formulations were designed to study factors 166 
influencing drug release profile. For example, different coating materials were used to study 167 
the effect of pore-forming agent on drug release. 168 
Optimization of EOP tablet 169 
In order to optimize the formulation of EOP tablet, a 2-factor, 3-level face-centered 170 
central composite design was applied in this study. Each factor was consisted of three groups 171 
of design points: the points of the full factorial design stayed at the factor level of −1 and +1; 172 
the points of the star design stayed at the levels of 0, −α and +α; and the center point stayed at 173 
the factor level of 0 27, 33. Compared with circumscribed central composite design, FCCD 174 
evaluated the factors at three levels with α = 1 (Table 2). Thus, the experimental trails were 175 
composed of 9 possible combinations, including 4 factorial points, 4 axial points and 5 176 
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central points (Table 3). 177 
Moreover, two independent variables (factors): CA: PEG-1500 ratio (X1) and weight gain 178 
(X2) were selected to study their effects on the release profile of the two drugs. The EOP 179 
tablet was designed to release drugs in 12 h with zero-order release rate. Thus, four dependent 180 
variables (responses): percentage of MTF released within 12 h (QMTF 12 h, Y1), R
2 of MTF 181 
release data fitted to zero-order equation (RSQMTF zero, Y2), percentage of GLZ released within 182 
12 h (QGLZ 12 h, Y3), and R
2 of GLZ release data fitted to zero-order equation (RSQGLZ zero, Y4) 183 
were selected to evaluate the release profiles. All experiments were performed in triplicate 184 
and randomized manner to eliminate a possible source of bias. 185 
The statistical experimental design was performed for model qualification. The 186 
regression coefficients were determined by the Design-Expert software (Version 8.0.5, 187 
Stat-Ease Inc., Minneapolis, USA). 188 
In vivo study in beagle dogs 189 
The protocol of in vivo study was approved by the university ethics committee under the 190 
guidance for care and use of laboratory animals. The in vivo study was performed in the 191 
department of laboratory animal research at Shenyang Pharmaceutical University (Shenyang, 192 
China). 193 
A randomized, two-period crossover design was conducted to evaluate in vivo 194 
performance of EOP tablet. Six healthy beagle dogs, weighing between 9 and 13 kg, were 195 
used in this study. The dogs were kept overnight fasting for at least 12 h prior to experiment 196 
with free access to water. All dogs were divided into two groups. One group was given two 197 
conventional tablets (each tablet contains 250 mg MTF with 2.5 mg GLZ), whereas the other 198 
10 
group was given one EOP tablet (containing 500 mg MTF with 5 mg GLZ). All formulations 199 
were administrated to dogs with 20 ml of water. A washout period of at least 7 days was 200 
required between two consecutive administrations. 201 
5 ml blood samples were obtained from cephalic vein at certain time points after 202 
administration. All blood samples were kept in heparinized tubes, and immediately 203 
centrifuged at 4000 rpm for 10 min. The plasma was removed and stored at −20 °C for 204 
further analysis. 205 
Sample preparation and analytical method 206 
Determination of plasma MTF concentration:  207 
0.2 ml plasma was added with 0.4 ml methanol before vortex for 1 min. The plasma was 208 
centrifuged at 12,000 rpm for 10 min. 20 μL of supernatant was directly injected into the 209 
column for HPLC analyses under the conditions describe below. 210 
The concentration of MTF in the blood sample was analyzed by HPLC34 (Beijing 211 
Purkinje General Instrument Co.,Ltd., Beijing, China). The separation of MTF was achieved 212 
on a Diamonsil C18 column (5 μm, 250 × 4.6 mm, Dikma). The mobile phase consisted of 2 213 
mm sodium dodecyl sulfate solution (0.25% (v/v) triethylamine, pH 3.6) and acetonitrile 214 
(64:36, v/v), and flow rate was 1.0 ml/min. The wavelength of UV detector was set at 233 nm. 215 
The injection volume was 20 μl. 216 
Determination of plasma GLZ concentration:  217 
0.5 ml plasma was added with 50 μl methnol solution of gliclazide (10 μg/ml) as internal 218 
standard. Then the plasma was added with 200 μl 0.4 M HCl before vortex for 30 s. Vortex 219 
the plasma for another 10 min with 3 ml diethyl ether. Then the plasma was centrifuged at 220 
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4,000 rpm for 5 min. The supernatant was removed and dried at 45 °C by nitrogen. The 221 
residue was subsequently reconstituted with 100 μl methanol and analyzed by HPLC. 222 
The concentration of GLZ in the blood sample was analyzed by HPLC35 (Beijing 223 
Purkinje General Instrument Co.,Ltd., Beijing, China). The separation of GLZ was achieved 224 
on a Diamonsil C18 column (5 μm, 200 × 4.6 mm, Dikma). The mobile phase consisted of 225 
water (0.1% (v/v) acetic acid, pH 3.4), acetonitrile, and methanol (55:35:10, v/v/v), and flow 226 
rate was 1.0 ml/min. The wavelength of UV detector was set at 225 nm. The injection volume 227 
was 20 μl. 228 
Data analysis and statistics 229 
 Data were analyzed by DAS 2.0 software (Mathematical Pharmacology Professional 230 
Committee of China, Shanghai, China). The maximum plasma concentration (Cmax) and time 231 
to reach the maximum plasma concentration (Tmax) were obtained directly from the curve. 232 
The area under the plasma concentration-time curve (AUC) was calculated by the trapezoidal 233 
rule. AUC and Cmax were log-transformed prior to analysis with t-test. Tmax was analyzed 234 
using nonparametric Wilcoxon test. Difference was considered significant with p value < 0.05. 235 
The relative bioavailability of test preparation was determined by the ratio of the test 236 
preparation AUC to the reference preparation AUC. The preparations were considered 237 
bioequivalent if the ratio stayed within the range of 80-125%. 238 
The relationship between in vitro cumulative release and the fraction of drug absorbed in 239 
vivo was established with in vitro and in vivo correlation (IVIVC) and coefficient correlation 240 
(R). 241 
Result and Discussion 242 
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Design of EOP tablet and the effect of different factors in relation with release profile  243 
Drug release profile of the initial formulation 244 
The initial formulation is established on the basis of a previous formulation with the 245 
expectation of sustained and synchronized release of MTF and GLZ (Table 1). Fig. 1 246 
illustrates the drug release profile of the initial formulation; the cumulative release of MTF in 247 
12 h is 83.2%, whereas the cumulative release of GLZ in 12 h is 25.0%.  A burst release 248 
phase lasts from 4 h to 6 h. Compared with of MTF, the release rate of GLZ is relatively low 249 
with less cumulative release of the drug in 12 h 250 
Effect of pH levels on drug release 251 
GLZ is insoluble in water with pKa at 5.9. In order to deliver GLZ in a sustained release 252 
manner, sufficient osmotic pressure plays an important role. More importantly, osmotic 253 
pressure is crucial in the preparation of EOP tablet especially for a poorly water-soluble drug 254 
36-38, such as GLZ. Therefore, high dose of MTF in the core tablet is used as an osmotic 255 
active agent to generate sufficient osmotic pressure for controlled release of GLZ. In this 256 
article, the solubility of GLZ varies with different pH levels. Fig. 2a-b (F01-F03) shows the 257 
impact of NaHCO3 on the release profile of the formulation. The release rate of GLZ is 258 
higher as the concentration of NaHCO3 rises. As a pH modifier, NaHCO3 changes pH of the 259 
solution in the tablet core, which eventually leads to higher solubility of GLZ 39, 40. With the 260 
help of high dose of MTF and pH modifier,  cumulative release of GLZ in 12 h improves 261 
more than threefold compared with the initial formulation 41.  262 
Effect of release retardant on drug release 263 
The high water-solubility of MTF comes with problem of burst release phase in a certain 264 
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formulation, resulting in difficulties in the control of drug release rate 42. As an impermeable 265 
polymer, ethyl cellulose (EC) is one of the materials with the capability to address this issue43, 266 
44. In this study, EC is added to the formulation as both binder and release retardant. Fig. 2a-b 267 
(F04-F06 and F07-F09) shows the release profiles of the formulation with different 268 
moistening agents. No burst release is observed from 4h to 6h and release profile is 269 
unaffected by different amounts of EC. 270 
Effect of pore-forming agent on drug release 271 
Fig. 2c-d (F10-F12 and F13-F15) shows the impact of different pore-forming agents, 272 
such as PEG, on the release profile of the formulation. PEG works by forming more pores on 273 
the membrane of the tablet, which leads to higher release rate of the drug 45. In this study, the 274 
release profiles of PEG-400, PEG-1500 and PEG-4000 are similar, whereas the release 275 
curves are significantly influenced PEG levels. As shown in the figures, the drug release rate 276 
(F13-F15) and cumulative release of both MTF and GLZ in 4 h increase when the PEG-1500 277 
level increases.  278 
Effect of membrane coating weight gain on drug release 279 
Fig. 2c-d (F16-F18) shows the impact of coating weight gain on the release profile of the 280 
formulations. It is observed that drug release rate and cumulative release decreases from F16 281 
to F18 for both MTF and GLZ. The result shows that the drug release rate decreases as the 282 
coating weight gain increases. When because coating weight gain decrease, water penetration 283 
across the membrane increase. Hence, tablet core is dissolved faster, and the release rate 284 
ascends. 285 
Optimization of EOP tablet 286 
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The traditional one-variable-at-a-time (OVAT) formulation optimization is in search of 287 
an optimal response from one certain variable by keeping all the other factors in fixed level. 288 
Design of Experiment (DoE) triumphs OVAT by improving interactions between factors. In 289 
our study, a two-factor, three-level face-centered central composite design (FCCD) is used for 290 
the optimal response of different factors in relation with the formulation. All factors are 291 
intentionally divided into two groups, the first group contains the factors in relation with core 292 
tablet, while the other group contains the factors affecting the property of the semi-permeable 293 
membrane. CA: PEG-1500 ratio and membrane coating thickness are selected for formulation 294 
optimization. By the calculation of design expert software, 13 possible formulations are 295 
generated (Table 3). In particular, F07 is selected as the optimal formulation for the core 296 
tablet.  297 
Statistical analysis and mathematical modeling 298 
The effect of independent parameters CA: PEG-1500 ratio (X1) and weight gain (X2) in 299 
responses to QMTF 12 h (Y1), RSQMTF zero (Y2), QGLZ 12 h (Y3), and RSQGLZ zero (Y4) are analyzed 300 
(Y1 and Y3 are drug cumulative release percentage , while Y2 and Y4 are R
2 of drug release data 301 
fitted to zero-order equation). The mathematical model for each response is generated and 302 
visualized by 3D model graph. The relationship between explanatory variables and responses 303 
are analyzed by multiple linear regression with better-fitting method which are shown in Eqs. 304 
(3) - (6) below. 305 
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Eqs. (3)-(6) reflect the quantitative influence of formulation variable: X1 (CA:PEG-1500 314 
ratio) and X2 (weight gain) and their interaction with response: Y1 (QMTF 12 h), Y2 (RSQMTF zero), 315 
Y3 (QGLZ 12 h), and Y4 (RSQGLZ 12 h). 316 
By analysis of variance (ANOVA), it indicates the quadratic regression model is suitable 317 
for every response Y1 (p < 0.0001), Y2 (p < 0.0001), Y3 (p < 0.0001) and Y4 (p < 0.0001). 318 
Meanwhile, data quality of the model for every response is measured. The value R2 indicates 319 
the proportion of variance of the model. The R2 values of the model are 0.975, 0.982, 0.998 320 
and 0.988 for Y1, Y2, Y3 and Y4, which represent 97.5%, 98.2%, 99.8% and 98.8% of the 321 
variance for the model. Adjusted R2 values for every response Y1, Y2, Y3 and Y4 are 0.958, 322 
0.969, 0.996 and 0.979, and the corresponding predicted R2 values are 0.851, 0.874, 0.993 323 
and 0.955 (Table 4). The adjusted R2 and predicted R2 are closer than 0.20, which indicates 324 
the predicted R2 is in agreement with the adjusted R2.The relationship between dependent 325 
variables, for example QMTF 12 h (Y1), RSQMTF zero (Y2), QGLZ 12 h (Y3), and RSQGLZ zero (Y4) and 326 
independent variables CA: PEG-1500 ratio (X1) weight gain (X2) are demonstrated in Fig. 327 
3a-d. The region of maxima (region in red) and minima (region in blue) for every 4 response 328 
16 
is visualized in the figure as well. 329 
Analysis of MTF release characteristics  330 
CA: PEG-1500 ratio (X1), weight gain (X2) and their interaction between QMTF 12 h (Y1) 331 
and RSQMTF zero (Y2) are shown in Eqs. (3) and (4). 332 
The regression equation is represented in function using x1, x2, and f (x1, x2) as X1, X2, 333 
and Y. Eqs. (3) is adpated to the function below. 334 
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The partial derivative f in relation with x1 and x2 is calculated, as shown below. 337 
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The above two partial derivate functions explain the variation of f in the x2 and x1 340 
direction. Indeed, ∂f/∂x1 gives an exact value for every point on the slope in the x1 direction. 341 
The value range of x1 in this study is 4 to 6, and that of x2 is 2.5 to 4.5. Thus, the value range 342 
of ∂f/∂x1 is an interval from 4.93 to −22.84, and the value range of ∂f/∂x2 is an interval from 343 
3.23 to −16.46. The change of partial derivative indicates QMTF 12 h (Y1) increases with CA: 344 
PEG-1500 ratio (X1) and weight gain (X2).  345 
Similarly, Eqs. (4) is established in the same manner. The value range of ∂f/∂x1 is an 346 
interval from 0.053 to −0.0076, and the value range of ∂f/∂x2 is an interval from 0.051 to 347 
−0.016. The change of the partial derivative also implies RSQMTF zero (Y2) increases with CA: 348 
PEG-1500 ratio (X1) and weight gain (X2). The maximum region is located in the upper 349 
17 
values of both CA: PEG-1500 ratio (X1) and weight gain (X2) where the derivative goes 350 
through zero. 351 
Fig. 3a and Fig. 3b also illustrate the quadratic relationship between CA: PEG-1500 ratio 352 
and weight gain. An increase in CA: PEG-1500 ratio from 4 to 6 and weight gain from 2.5 to 353 
4.5 results in fall in the graph of QMTF 12 h and rise in the graph of RSQMTF zero. Moreover, the 354 
graphical analysis is coincident with the mathematical analysis. 355 
Analysis of GLZ release characteristics  356 
 CA: PEG-1500 ratio (X1), weight gain (X2), the release profile of GLZ in 12 h (Y3) and 357 
correlation coefficient (Y4) are illustrated in Eqs. (5) and (6). 358 
The analysis is similar with MTF. In Eqs. (5), the value range of ∂f/∂x1 is an interval from 359 
0.45 to -10.58, and the value range of ∂f/∂x2 is an interval from −1.88 to −7.35. The change of 360 
partial derivative ∂f/∂x1 indicates QGLZ 12 h (Y3) increases with CA:PEG-1500 ratio (X1).  361 
In Eqs. (6), the value range of ∂f/∂x1 is an interval from 0.071 to −0.016, and the value 362 
range of ∂f/∂x2 is an interval from 0.055 to −0.011. The change of partial derivative indicates 363 
RSQGLZ zero (Y4) increases with CA:PEG-1500 ratio (X1) and weight gain (X2).  364 
Fig. 3c and Fig. 3d illustrate the quadratic relationship between the CA: PEG-1500 ratio 365 
and weight gain. The increase in CA: PEG-1500 ratio from 4 to 6 and weight gain from 2.5 to 366 
4.5 results in fall in the graph of QGLZ 12 h and rise in the graph of RSQGLZ zero. The graphical 367 
analysis is coincident with the mathematical analysis. 368 
Therefore, the similarity of release characteristics of CA: PEG-1500 ratio and weight 369 
gain indicates the release of MTF and GLZ are affected by the two factors synchronizely. 370 
Formulation optimization 371 
18 
Y1 and Y3 are cumulative release percentage and expected to be maximized, while Y2 and 372 
Y4 are R
2 of drug release data fitted to zero-order equation and expected to be close 1. Based 373 
on this standard, the optimized regions are represented in red color in Fig.3. The overlapping 374 
region shows the optimal formulation in response to every factor. The relationship between 375 
experimental values and predicted ones are in agreement (Table 5). The cumulative release 376 
profile of the optimized formulation is illustrated in Fig.4. The f2 value of the release of MTF 377 
and GLZ is 70, which indicates the two drugs release synchronously. 378 
In vivo study in beagle dogs 379 
The main pharmaceutical parameters, such as Cmax, Tmax, AUC(0-24 h) and AUC(0-∞) are 380 
listed in Table 6. Fig. 5a-b shows the pharmacokinetics profiles in beagle dogs of the 381 
optimized formulation. In comparison with conventional tablets, drug plasma concentration 382 
of optimized formulation rises with relatively low peak. The relative bioavailability of 383 
optimized formulation is 99.2% and 99.3% for MTF and GLZ, respectively. The 90% 384 
confidence interval of the AUC (0-∞) of optimized formulation is 84.9-113.8% for MTF and 385 
83.2-112.3% for GLZ. Moreover, by analysis of DAS 2.0 software and Wagner-Nelson 386 
method, it displays acceptable correlation parameter (R = 0.9699 for MTF and 0.9595 for 387 
GLZ) which implies in vitro drug release is in agreement with in vitro absorption. 388 
 389 
Conclusion 390 
In this study, compound EOP tablet of MTF and GLZ is designed to take advantage of 391 
the combination of two drugs and achieve prolonged steady blood drug level. In this EOP 392 
system, MTF is not only an active ingredient, but also acts as an osmotic agent to generate 393 
19 
sufficient osmotic pressure to facilitate the release of GLZ. Among all the factors in relation 394 
with the release rate of the drugs, pore-forming agent ratio and membrane coating thickness 395 
play an important role. Moreover, the formulation of EOP tablet is optimized by a 396 
face-centered central composite design (FCCD) for better controlled release profile. Then the 397 
optimal formulation is further validated both by in vitro and in vivo study, which shows 398 
zero-order release profile in vitro and displays prolonged blood drug concentration-time 399 
profile in vivo. At the same time, in vitro and in vivo correlation for MTF and GLZ of the 400 
EOP tablet is desirable. Overall, a highly water-soluble drug MTF and poorly water-soluble 401 
drug GLZ are delivered in sustained and synchronized manner in vitro and in vivo. 402 
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Table 1 
Formulations Core tablet  Coating 
 MTF (mg) GLZ (mg) PVP K-90 (mg) NaHCO3 (mg) Ethanol (%) EC (mg)  PEG type CA:PEG ratio Weight gain (%) 
Finitial 500 5 25 0 70 0  1500 7:1 3.5 
F01, F02, F03 500 5 25 5, 10, 15 70 0  1500 7:1 3.5 
F04, F05, F06 500 5 25 10 70, 95, 100 10  1500 7:1 3.5 
F07, F08, F09 500 5 25 10 95 5, 10, 15  1500 7:1 3.5 
F10, F11, F12 500 5 25 10 95 5  400, 1500, 4000 7:1 3.5 
F13, F14, F15 500 5 25 10 95 5  1500 7:1, 5:1, 3:1 3.5 
F16, F17, F18 500 5 25 10 95 5  1500 5:1 3.5, 5.0, 6.5 
26 
Table 2 
 Levels used 
Independent variable, factor −1 (−α) −1 0 1 1 (+α) 
X1 = CA:PEG-1500 ratio 4:1 4:1 5:1 6:1 6:1 
X2 = Weigh gain (%) 2.5 2.5 3.5 4.5 4.5 
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Table 3 
 
 
Formulation batches Coded factors  Actual values of variable 
X1 X2  CA:PEG-1500 ratio Weigh gain (%) 
Factorial points      
B1 1 1  6:1 4.5 
B2 −1 −1  4:1 2.5 
B3 −1 1  4:1 4.5 
B4 1 −1  6:1 2.5 
Center points      
B5 0 0  5:1 3.5 
B6 0 0  5:1 3.5 
B7 0 0  5:1 3.5 
B8 0 0  5:1 3.5 
B9 0 0  5:1 3.5 
Axial points      
B10 −1 (−α) 0  4:1 3.5 
B11 0 −1 (−α)  5:1 2.5 
B12 1 (+α) 0  6:1 3.5 
B13 0 1 (+α)  5:1 4.5 
28 
Table 4 1 
 2 
Term Model fitting P-value Predicted R2 Adjusted R2 
Y1 
2
2
2
121211
62414.2
64414.459750.474313.3457930.5316516.68
X
XXXXXY


 
< 0.0001 0.851 0.958 
Y2 
2
2
2
1
21212
00311897.8003
66897.6017050.015947.014913.024732.0
XX
XXXXY
E
E


 
< 0.0001 0.874 0.969 
Y3 
2
2
2
121213
19000.0
58000.135250.247917.896708.1882375.53
X
XXXXXY


 
< 0.0001 0.993 0.996 
Y4 
2
2
2
121214
00387586.6
011926.0019575.016811.021522.0041355.0
X
XXXXXY
E 

 
< 0.0001 0.955 0.979 
Y1 (QMTF 12 h): percentage of MTF released within 12 h; Y2 (RSQMTF zero):R
2 of MTF release data fitted to zero-order equation; 3 
Y3 (QGLZ 12 h): percentage of GLZ released within 12 h, Y4 (RSQGLZ zero):R
2 of GLZ release data fitted to zero-order equation  4 
 5 
 6 
 7 
 8 
 9 
 10 
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Table 5 11 
X1 X2 (%) Response Predicted value Actual value Bias (%) 
5:1 3.5 
Y1 (%) 92.63 93.51 0.9500 
Y2 0.9865 0.9860 −0.0506 
Y3 (%) 95.34 95.27 −0.0734 
Y4 0.9809 0.9829 0.2039 
 12 
 13 
 14 
Table 6  15 
Formulation MTF  GLZ 
Cmax 
(μg/mL) 
Tmax 
(h) 
AUC(0-24 h) 
(μg/mL h) 
AUC(0-∞) 
(μg/mL h) 
 Cmax 
(ng/mL) 
Tmax 
(h) 
AUC(0-24 h) 
(ng/mL h) 
AUC(0-∞) 
(ng/mL h) 
Conventional tablet 12.28 ± 2.73 1.42 ± 0.38 53.07 ± 8.02 57.84 ± 10.10  1410.67 ± 321.16 1.67 ± 0.41 7732.75 ± 1298.30 8621.11 ± 1642.05 
EOP tablet 6.36 ± 1.95 4.08 ± 0.97 52.64 ± 10.63 56.43 ± 6.37  853.33 ± 214.14 4.17 ± 0.93 7469.46 ± 1382.63 8689.26 ± 3609.19 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
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Fig. 1 In vitro release profiles of the initial formulation of MTF and GLZ. 
 
Fig. 2a In vitro release profiles of MTF with different core tablets 
F01, F02 and F03 show the impact of NaHCO3 on MTF release, while F04, F05, F06 and F07 
show the effect of release retardant on MTF release 
 
Fig. 2b In vitro release profiles of GLZ with different core tablets 
F01, F02 and F03 show the impact of NaHCO3 on GLZ release, while F04, F05, F06 and F07 
show the effect of release retardant on GLZ release 
 
Fig. 2c In vitro release profiles of MTF with different coating membrane 
F10, F11, F12, F13, F14 and F15 show the impact of different pore-forming agents on MTF 
release, while F16, F17 and F18 show the effect of coating weight gain on MTF release 
 
Fig. 2d In vitro release profiles of GLZ with different coating membrane 
F10, F11, F12, F13, F14 and F15 show the impact of different pore-forming agents on GLZ 
release, while F16, F17 and F18 show the effect of coating weight gain on GLZ release 
  
Fig. 3 Response surface for (a) the release percent of MTF within 12 h (Y1), (b) R
2 of MTF 
release data fitted to zero-order equation (Y2), (c) the release percent of GLZ within 12 h (Y3), 
and (d) R2 of GLZ release data fitted to zero-order equation (Y4) as function of CA:PEG-1500 
ratio (X1) and weigh gain (X2) 
 
Fig. 4 In vitro release profiles of the optimized formulation with MTF and GLZ. 
 
Fig. 5 In vivo pharmacokinetics profiles of (a) MTF and (b) GLZ in beagle dogs from the 
conventional tablets and the EOP tablets (n = 6) 
Fig. 6 In vivo-in vitro correlation for MTF and GLZ of the EOP tablets 
Figure 1 
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